<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01273207</url>
  </required_header>
  <id_info>
    <org_study_id>110064</org_study_id>
    <secondary_id>11-H-0064</secondary_id>
    <nct_id>NCT01273207</nct_id>
  </id_info>
  <brief_title>Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans</brief_title>
  <official_title>Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bronchiolitis Obliterans (BO) is an obstructive lung disease that can affect individuals that&#xD;
      have undergone a lung or hematopoietic stem cell transplant. BO has been studied most&#xD;
      extensively in lung transplant recipients, where it is considered to represent chronic lung&#xD;
      rejection. It is the leading cause of death after lung transplant, with mortality rates up to&#xD;
      55 percent. In hematopoietic stem cell transplantation, BO is thought to be a manifestation&#xD;
      of chronic graft-vs-host disease (GVHD). Up to 45 percent of patients undergoing&#xD;
      hematopoietic stem cell transplantation at the NHLBI develop a decline in pulmonary function.&#xD;
      Conventional therapy for patients who develop BO consists of augmentation of systemic&#xD;
      immunosuppressants. Systemic immunosuppression has limited efficacy for BO and is associated&#xD;
      with deleterious consequences including increased risk of infections and decreased&#xD;
      graft-versus tumor/leukemia effects.&#xD;
&#xD;
      Recently, cyclosporine inhalation solution (CIS) in solution with propylene glycol has been&#xD;
      shown to improve overall survival and chronic rejection-free survival in lung transplant&#xD;
      patients. These findings suggest targeted delivery of immunosuppressive therapy to the&#xD;
      diseased organ warrants further investigation as this may minimize the morbidity associated&#xD;
      with systemic immunosuppression. However, there currently exists limited data regarding the&#xD;
      overall efficacy of inhaled cyclosporine to treat established BO following lung&#xD;
      transplantation. Furthermore, inhaled cyclosporine has not been studied in the treatment of&#xD;
      BO following hematopoietic stem cell transplantation.&#xD;
&#xD;
      Here, we propose to evaluate the long-term safety and efficacy, of inhaled CIS for the&#xD;
      treatment of BO. Enrollment will be offered to subjects who have completed the end of study&#xD;
      (week 18 visit) for the initial protocol (Phase II Trial of CIS in lung transplant and&#xD;
      hematopoietic stem cell transplant recipients for treatment of Bronchiolitis Obliterans) and&#xD;
      who have shown evidence of benefit (either an improvement or stabilization) in BO/BOS with&#xD;
      CIS treatment.&#xD;
&#xD;
      Clinical parameters, including pulmonary function tests, will be measured in addition to&#xD;
      laboratory markers of the anti-inflammatory response to CIS. Adverse events associated with&#xD;
      extended treatment with CIS will be recorded.&#xD;
&#xD;
      The primary objective is to provide long-term safety and efficacy data for the use of CIS in&#xD;
      hematopoietic transplant patients and lung transplant patients with established BO.&#xD;
&#xD;
      Secondary objectives include investigation of the inflammatory pathways that lead to chronic&#xD;
      BO and ascertainment of the long term anti-inflammatory effects of this CSA preparation ex&#xD;
      vivo and in vivo.&#xD;
&#xD;
      Primary endpoint is the efficacy of extended use CIS for BO/BOS. Secondary endpoints include&#xD;
      the toxicity profile (adverse events), improvement in high resolution chest CT images,&#xD;
      results of peripheral blood and bronchoalveolar cytokine arrays to assess secondary markers&#xD;
      of inflammation, and functional capacity measurements using a six-minute walk test.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bronchiolitis Obliterans (BO) is an obstructive lung disease that can affect individuals that&#xD;
      have undergone a lung or hematopoietic stem cell transplant. BO has been studied most&#xD;
      extensively in lung transplant recipients, where it is considered to represent chronic lung&#xD;
      rejection. It is the leading cause of death after lung transplant, with mortality rates up to&#xD;
      55 percent. In hematopoietic stem cell transplantation, BO is thought to be a manifestation&#xD;
      of chronic graft-vs-host disease (GVHD). Up to 45 percent of patients undergoing&#xD;
      hematopoietic stem cell transplantation at the NHLBI develop a decline in pulmonary function.&#xD;
      Conventional therapy for patients who develop BO consists of augmentation of systemic&#xD;
      immunosuppressants. Systemic immunosuppression has limited efficacy for BO and is associated&#xD;
      with deleterious consequences including increased risk of infections and decreased&#xD;
      graft-versus tumor/leukemia effects.&#xD;
&#xD;
      Recently, cyclosporine inhalation solution (CIS) in solution with propylene glycol has been&#xD;
      shown to improve overall survival and chronic rejection-free survival in lung transplant&#xD;
      patients. These findings suggest targeted delivery of immunosuppressive therapy to the&#xD;
      diseased organ warrants further investigation as this may minimize the morbidity associated&#xD;
      with systemic immunosuppression. However, there currently exists limited data regarding the&#xD;
      overall efficacy of inhaled cyclosporine to treat established BO following lung&#xD;
      transplantation. Furthermore, inhaled cyclosporine has not been studied in the treatment of&#xD;
      BO following hematopoietic stem cell transplantation.&#xD;
&#xD;
      Here, we propose to evaluate the long-term safety and efficacy, of inhaled CIS for the&#xD;
      treatment of BO. Enrollment will be offered to subjects who have completed the end of study&#xD;
      (week 18 visit) for the initial protocol (Phase II Trial of CIS in lung transplant and&#xD;
      hematopoietic stem cell transplant recipients for treatment of Bronchiolitis Obliterans) and&#xD;
      who have shown evidence of benefit (either an improvement or stabilization) in BO/BOS with&#xD;
      CIS treatment.&#xD;
&#xD;
      Clinical parameters, including pulmonary function tests, will be measured in addition to&#xD;
      laboratory markers of the anti-inflammatory response to CIS. Adverse events associated with&#xD;
      extended treatment with CIS will be recorded.&#xD;
&#xD;
      The primary objective is to provide long-term safety and efficacy data for the use of CIS in&#xD;
      hematopoietic transplant patients and lung transplant patients with established BO.&#xD;
&#xD;
      Secondary objectives include investigation of the inflammatory pathways that lead to chronic&#xD;
      BO and ascertainment of the long term anti-inflammatory effects of this CSA preparation ex&#xD;
      vivo and in vivo.&#xD;
&#xD;
      Primary endpoint is the efficacy of extended use CIS for BO/BOS. Secondary endpoints include&#xD;
      the toxicity profile (adverse events), improvement in high resolution chest CT images,&#xD;
      results of peripheral blood and bronchoalveolar cytokine arrays to assess secondary markers&#xD;
      of inflammation, and functional capacity measurements using a six-minute walk test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2, 2012</start_date>
  <completion_date type="Actual">May 23, 2019</completion_date>
  <primary_completion_date type="Actual">May 10, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Lung Function - Increase in FEV1</measure>
    <time_frame>6 Months</time_frame>
    <description>Continued improvement in lung function as defined by 10% or more increase in FEV1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Stablization - Decrease in FEV1 or Less Than 10% Increase in FEV1</measure>
    <time_frame>6 Months</time_frame>
    <description>Stabilization in Pulmonary Function Test (PFT) as defined by less than 10% increase in FEV1 or less than 10% decline in FEV1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Progression - Decrease in FEV1 or Additional/Increase in Immunosuppressive Therapies</measure>
    <time_frame>6 Months</time_frame>
    <description>Disease progression as defined by a 20% or more decline in FEV1, or those who require an increase in immunosuppressive therapies by at least 25% or the addition of new immunosuppressive therapies.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Bronchiolitis Obliterans</condition>
  <condition>Constructive Bronchiolitis</condition>
  <condition>Graft Versus Host Disease</condition>
  <condition>Bronchiolitis, Exudative</condition>
  <condition>Bronchiolitis, Proliferative</condition>
  <condition>Graft-Versus-Host Disease</condition>
  <arm_group>
    <arm_group_label>Inhaled Cyclosporine in HSCT Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemopoietic Stem Cell transplant (HSCT) subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) at maximum tolerated dose not exceeding 300 mg administered three times per week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine Inhalation Solution (CIS)</intervention_name>
    <description>CIS is a sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.</description>
    <arm_group_label>Inhaled Cyclosporine in HSCT Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
               1. Completed the End of Study visit (week 19) on the initial protocol (Phase II&#xD;
                  Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and&#xD;
                  Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis&#xD;
                  Obliterans) in the preceding 12 weeks&#xD;
&#xD;
               2. Patients have shown evidence for a clinical benefit to CIS as evidenced by one or&#xD;
                  more of the following:&#xD;
&#xD;
          -  Improvement in pulmonary function defined by a 10 percent or more increase in the FEV1&#xD;
             at week 18, confirmed with repeat PFTs at least 1 week apart.&#xD;
&#xD;
          -  In patients with progressive disease at study entry on the initial protocol (Phase II&#xD;
             Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic&#xD;
             Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans),&#xD;
             stabilization in pulmonary function, defined as less than a 10 percent improvement in&#xD;
             FEV1 or less than 10 percent decline in FEV1 at week 18, confirmed with repeat PFTs at&#xD;
             least 1 week apart.&#xD;
&#xD;
          -  In patients with stable disease (active BOS stable by FEV1 criteria) at study entry on&#xD;
             the initial protocol (Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung&#xD;
             Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of&#xD;
             Bronchiolitis Obliterans), stabilization in pulmonary function, defined as less than a&#xD;
             10 percent improvement in their FEV1 or less than 10 percent decline in FEV1, and a&#xD;
             decrease in the dose of one or more systemic immunosuppressants by at least 20 percent&#xD;
             (sustained for 3 weeks, excluding adjustments made for target drug levels). * The&#xD;
             criteria for study entry on this extension protocol are not the same as the criteria&#xD;
             for response on the primary protocol to allow for entry of patients on this extension&#xD;
             protocol, which is deriving some clinical benefit, but have not met the full response&#xD;
             criteria as defined in the primary protocol.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. More than a 12 week gap in study drug administration (CIS)&#xD;
&#xD;
          2. Evidence of uncontrolled, pulmonary infection&#xD;
&#xD;
          3. ECOG performance status greater than or equal to 3&#xD;
&#xD;
          4. Patient pregnant or breast feeding or not willing to continue the use of an approved&#xD;
             method of birth control&#xD;
&#xD;
          5. Life expectancy less than 18 weeks&#xD;
&#xD;
          6. History of hypersensitivity reaction to propylene glycol&#xD;
&#xD;
          7. Documented allergy or intolerance to CIS&#xD;
&#xD;
          8. History of untreated coronary insufficiency, severe cardiac arrhythmias, and/or&#xD;
             uncontrolled hypertension.&#xD;
&#xD;
          9. Serum creatinine greater than 2.5 mg/dl&#xD;
&#xD;
         10. Inability to comprehend the investigational nature of the study and provide informed&#xD;
             consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole J Gormley, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2011-H-0064.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>August 14, 2019</verification_date>
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <results_first_submitted>August 31, 2020</results_first_submitted>
  <results_first_submitted_qc>August 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2020</results_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Blood Stem Cell Transplant</keyword>
  <keyword>Inhaled Cyclosporine</keyword>
  <keyword>Graft-Versus-Host Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT01273207/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The lung transplant arm was closed during the study due to lack of subject enrollment</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Cyclosporine in HSCT Participants</title>
          <description>Hemopoietic Stem Cell transplant (HSCT) subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) at maximum tolerated dose not exceeding 300 mg administered three times per week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Cyclosporine in HSCT Participants</title>
          <description>Hemopoietic Stem Cell transplant (HSCT) subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) at maximum tolerated dose not exceeding 300 mg administered three times per week</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Status of Pulmonary Disease at Initial Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Stable Pulmonary Disease (Stable FEV1)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Pulmonary Disease (Declining FEV1)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Lung Function - Increase in FEV1</title>
        <description>Continued improvement in lung function as defined by 10% or more increase in FEV1</description>
        <time_frame>6 Months</time_frame>
        <population>Inhaled Cyclosporine in hematopoietic stem cell transplant (HSCT) participants</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Cyclosporine in HSCT Participants</title>
            <description>Hemopoietic Stem Cell transplant (HSCT) subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) at maximum tolerated dose not exceeding 300 mg administered three times per week</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Lung Function - Increase in FEV1</title>
          <description>Continued improvement in lung function as defined by 10% or more increase in FEV1</description>
          <population>Inhaled Cyclosporine in hematopoietic stem cell transplant (HSCT) participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease Stablization - Decrease in FEV1 or Less Than 10% Increase in FEV1</title>
        <description>Stabilization in Pulmonary Function Test (PFT) as defined by less than 10% increase in FEV1 or less than 10% decline in FEV1</description>
        <time_frame>6 Months</time_frame>
        <population>Inhaled Cyclosporine in hematopoietic stem cell transplant (HSCT) participants</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Cyclosporine in HSCT Participants</title>
            <description>Hemopoietic Stem Cell transplant (HSCT) subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) at maximum tolerated dose not exceeding 300 mg administered three times per week</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Stablization - Decrease in FEV1 or Less Than 10% Increase in FEV1</title>
          <description>Stabilization in Pulmonary Function Test (PFT) as defined by less than 10% increase in FEV1 or less than 10% decline in FEV1</description>
          <population>Inhaled Cyclosporine in hematopoietic stem cell transplant (HSCT) participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease Progression - Decrease in FEV1 or Additional/Increase in Immunosuppressive Therapies</title>
        <description>Disease progression as defined by a 20% or more decline in FEV1, or those who require an increase in immunosuppressive therapies by at least 25% or the addition of new immunosuppressive therapies.</description>
        <time_frame>6 Months</time_frame>
        <population>Inhaled Cyclosporine in hematopoietic stem cell transplant (HSCT) participants</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Cyclosporine in HSCT Participants</title>
            <description>Hemopoietic Stem Cell transplant (HSCT) subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) at maximum tolerated dose not exceeding 300 mg administered three times per week</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Progression - Decrease in FEV1 or Additional/Increase in Immunosuppressive Therapies</title>
          <description>Disease progression as defined by a 20% or more decline in FEV1, or those who require an increase in immunosuppressive therapies by at least 25% or the addition of new immunosuppressive therapies.</description>
          <population>Inhaled Cyclosporine in hematopoietic stem cell transplant (HSCT) participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Cyclosporine in HSCT Participants</title>
          <description>Hemopoietic Stem Cell transplant (HSCT) subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) at maximum tolerated dose not exceeding 300 mg administered three times per week</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Post transplant lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sputum culture positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoglobinaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Richard Childs</name_or_title>
      <organization>National Heart Lung and Blood Institute</organization>
      <phone>+301-451-7128</phone>
      <email>childsr@nhlbi.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

